JP7579057B2 - 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤 - Google Patents

血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤 Download PDF

Info

Publication number
JP7579057B2
JP7579057B2 JP2019534124A JP2019534124A JP7579057B2 JP 7579057 B2 JP7579057 B2 JP 7579057B2 JP 2019534124 A JP2019534124 A JP 2019534124A JP 2019534124 A JP2019534124 A JP 2019534124A JP 7579057 B2 JP7579057 B2 JP 7579057B2
Authority
JP
Japan
Prior art keywords
sox18
cancer
alkyl
protein
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019534124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506884A (ja
JP2020506884A5 (enExample
Inventor
マティアス フランソワ
ヨハネス ゾイッグ
イェルン オーヴェルマン
スレーマン クマル マミディアラ
アンジェラ アグスルヤルティ サリム
フランク ロジャー フォンテーン
マシュー アリスター クーパー
ロバート ジョン カポン
アヴリル アレクシス バーバラ ロバートソン
Original Assignee
ザ ユニバーシティー オブ クイーンズランド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905362A external-priority patent/AU2016905362A0/en
Application filed by ザ ユニバーシティー オブ クイーンズランド filed Critical ザ ユニバーシティー オブ クイーンズランド
Publication of JP2020506884A publication Critical patent/JP2020506884A/ja
Publication of JP2020506884A5 publication Critical patent/JP2020506884A5/ja
Priority to JP2022162614A priority Critical patent/JP2023011613A/ja
Application granted granted Critical
Publication of JP7579057B2 publication Critical patent/JP7579057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/331—Polycyclic acids with all carboxyl groups bound to non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019534124A 2016-12-23 2017-12-21 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤 Active JP7579057B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022162614A JP2023011613A (ja) 2016-12-23 2022-10-07 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905362A AU2016905362A0 (en) 2016-12-23 Compounds and use thereof in methods of treatment
AU2016905362 2016-12-23
PCT/AU2017/051439 WO2018112545A1 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162614A Division JP2023011613A (ja) 2016-12-23 2022-10-07 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤

Publications (3)

Publication Number Publication Date
JP2020506884A JP2020506884A (ja) 2020-03-05
JP2020506884A5 JP2020506884A5 (enExample) 2021-01-28
JP7579057B2 true JP7579057B2 (ja) 2024-11-07

Family

ID=62624141

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534124A Active JP7579057B2 (ja) 2016-12-23 2017-12-21 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤
JP2022162614A Pending JP2023011613A (ja) 2016-12-23 2022-10-07 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022162614A Pending JP2023011613A (ja) 2016-12-23 2022-10-07 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤

Country Status (8)

Country Link
US (3) US11434190B2 (enExample)
EP (1) EP3558293A4 (enExample)
JP (2) JP7579057B2 (enExample)
KR (1) KR102572077B1 (enExample)
CN (1) CN110536685A (enExample)
AU (1) AU2017383102B2 (enExample)
CA (1) CA3048040A1 (enExample)
WO (1) WO2018112545A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110536685A (zh) 2016-12-23 2019-12-03 昆士兰大学 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病
CN110143941B (zh) * 2019-06-04 2021-05-25 北京四环制药有限公司 一种巴罗萨韦玛波酯中间体的合成方法
CA3190768A1 (en) * 2020-08-26 2022-03-03 Mathias Frederic FRANCOIS Antiviral sox inhibitors
CN118834915A (zh) * 2024-08-15 2024-10-25 扬州大学 一种在羊毛乳头细胞中稳定过表达的sox18慢病毒重组标签载体的构建及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074753A1 (de) 2000-03-30 2001-10-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Synthetische derivate von lunularsäure, arzneimittel enthaltend diese verbindungen, verfahren zur herstellung der lunularsäurederivate sowie deren verwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01503303A (ja) 1987-05-19 1989-11-09 フアイソンズ・ピーエルシー 化合物
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
CN101062043B (zh) 2006-04-30 2011-06-08 浙江天皇药业有限公司 3,4,5,4'-四甲氧基二苯乙烷-3’-o-磷酸二钠在抗肿瘤及其转移药物的应用
CN101235003B (zh) 2007-02-01 2010-09-15 浙江赛尔生物医学研究有限公司 3,4,5,4'-四甲氧基-α,β-二苯乙烷-3'-O-硫酸酯钠盐及其应用
JP2012505185A (ja) * 2008-10-13 2012-03-01 ノバルティス アーゲー ファルネシルピロホスフェートシンターゼ活性阻害剤であるサリチル酸誘導体
CA2794266C (en) * 2010-03-24 2020-09-08 Ohio University Compositions and methods for glucose transport inhibition
CN102050759A (zh) 2010-12-09 2011-05-11 江苏天晟药业有限公司 白藜芦醇酰胺类衍生物及其制备方法
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2015061779A1 (en) * 2013-10-25 2015-04-30 Wayne State University Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming
CN110536685A (zh) * 2016-12-23 2019-12-03 昆士兰大学 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病
CA3190768A1 (en) * 2020-08-26 2022-03-03 Mathias Frederic FRANCOIS Antiviral sox inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074753A1 (de) 2000-03-30 2001-10-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Synthetische derivate von lunularsäure, arzneimittel enthaltend diese verbindungen, verfahren zur herstellung der lunularsäurederivate sowie deren verwendung

Also Published As

Publication number Publication date
JP2020506884A (ja) 2020-03-05
CA3048040A1 (en) 2018-06-28
US20230100768A1 (en) 2023-03-30
CN110536685A (zh) 2019-12-03
AU2017383102A1 (en) 2019-08-01
AU2017383102B2 (en) 2023-05-11
JP2023011613A (ja) 2023-01-24
US12410116B2 (en) 2025-09-09
WO2018112545A1 (en) 2018-06-28
EP3558293A1 (en) 2019-10-30
KR102572077B1 (ko) 2023-08-29
US20190337880A1 (en) 2019-11-07
US20240002326A1 (en) 2024-01-04
EP3558293A4 (en) 2020-10-28
KR20190105018A (ko) 2019-09-11
US11434190B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
US12410116B2 (en) Compounds and use thereof in methods of treatment
Holden et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling
Stanley et al. Dysregulation and therapeutic targeting of RNA splicing in cancer
Bouché et al. Benzoisoquinolinediones as potent and selective inhibitors of BRPF2 and TAF1/TAF1L bromodomains
Smith et al. Antiproliferative and antimigratory effects of a novel YAP–TEAD interaction inhibitor identified using in silico molecular docking
Pobbati et al. Emerging roles of TEAD transcription factors and its coactivators in cancers
JP6592071B2 (ja) ヒトｅｚｈ２の阻害剤およびその使用方法
Hay et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains
Eggert et al. Discovery and characterization of a highly potent and selective aminopyrazoline-based in vivo probe (BAY-598) for the protein lysine methyltransferase SMYD2
Tamburri et al. Polycomb-dependent histone H2A ubiquitination links developmental disorders with cancer
Wang et al. Development of potent type I protein arginine methyltransferase (PRMT) inhibitors of leukemia cell proliferation
An et al. A-Raf: A new star of the family of raf kinases
Bata et al. Inhibitors of the Hippo pathway kinases STK3/MST2 and STK4/MST1 have utility for the treatment of acute myeloid leukemia
CN102271668B (zh) 表观遗传调控的小分子调节剂和其治疗应用
JP2019508496A (ja) 癌の治療法のためのｔａｆ１阻害剤
Quesada et al. The molecular biology of soft‐tissue sarcomas and current trends in therapy
Chang et al. Discovery of novel PROTAC degraders of p300/CBP as potential therapeutics for hepatocellular carcinoma
Shukla et al. Mutations of RNA splicing factors in hematological malignancies
Miller et al. Diarylthiophenes as inhibitors of the pore-forming protein perforin
Yap et al. Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein–protein and protein–DNA interactions
Du et al. Discovery and synthesis of a naturally derived protein kinase inhibitor that selectively inhibits distinct classes of serine/threonine kinases
Chen et al. A single nucleotide polymorphism located in microRNA-499a causes loss of function resulting in increased expression of osbpl1a and reduced serum HDL level
Sun et al. Structure-guided discovery of potent and selective CLK2 inhibitors for the treatment of knee osteoarthritis
Uguen et al. Tudor-Containing Methyl-Lysine and Methyl-Arginine Reader Proteins: Disease Implications and Chemical Tool Development
Liu et al. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221007

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221128

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221129

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221223

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241025

R150 Certificate of patent or registration of utility model

Ref document number: 7579057

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150